Cerebrospinal fluid biomarker profiling in corticobasal degeneration: Application of the AT(N) and other classification systems. (January 2021)

• Record Type: Journal Article
• Authors: Constantinides, Vasilios C.; Paraskevas, George P.; Boufidou, Fotini; Bourbouli, Mara; Stefanis, Leonidas; Kapaki, Elisabeth
• Is Part Of: Parkinsonism & related disorders. Volume 82(2021)
• Page Start: 44
• Page End: 49
• Publication Date: 2021-01
• Subjects: Corticobasal degeneration -- Corticobasal syndrome -- Alzheimer's disease -- Biomarkers -- Cerebrospinal fluid -- Tau proteins -- Amyloid-beta; AD Alzheimer's disease -- FTD frontotemporal degeneration -- CBS corticobasal syndrome -- CBD corticobasal degeneration -- PPA primary progressive aphasia -- NAV non-fluent agrammatic variant of primary progressive aphasia -- FBS frontal-behavioral spatial syndrome -- CSF cerebrospinal fluid -- Aβ42 amyloid beta with 42 amino acids -- τT total tau protein -- τP-181 tau protein phosphorylated at threonine 181 -- BIOMARKAPD Biomarkers for Alzheimer's disease and Parkinson's disease -- ABSI Alzheimer's Biomarkers Standardization Initiative 107289285; Parkinson's disease -- Periodicals; Movement disorders -- Periodicals; Movement Disorders -- Periodicals; Nerve Degeneration -- Periodicals; Nervous System Diseases -- Periodicals; Parkinson Disease -- Periodicals; Tremor -- Periodicals; Parkinson, Maladie de -- Périodiques; Parkinson's disease; 616.833
• DOI: 10.1016/j.parkreldis.2020.11.016
• Languages: English
• ISSNs: 1353-8020

Abstract

Abstract: Introduction: Total tau (τT), phosphorylated tau (τP-181) and amyloid beta (Aβ42) are cerebrospinal fluid (CSF) biomarkers of Alzheimer's disease (AD). There is no consensus on the interpretation criteria of these biomarkers. The aim of this study was to apply three different sets of criteria for CSF AD biomarker interpretation in a cohort of corticobasal degeneration (CBD) patients. Method: SForty patients fulfilling diagnostic criteria for "probable CBD" were included. The AT(N), BIOMARKAPD/ABSI and the τP-181/Aβ42 ratio criteria were applied. Results: The AT(N) criteria categorized 50% of "probable CBD" patients as AD, and 62.5% as harboring amyloid pathology. The BIOMARKAPD/ABSI and τP- 181/Aβ42 criteria categorized ~40% of "probable CBD" patients as AD. Discussion: Use of different interpretation criteria for CSF AD biomarkers produces diverse results. AD pathology is common in patients fulfilling "probable" CBD criteria. CBD diagnostic criteria may have suboptimal positive predictive value. A consensus regarding interpretation criteria of CSF AD biomarkers is pivotal. Highlights: The AT(N) system classifies 50% of "probable" CBD patients as AD and 62.5% as harboring amyloid pathology. The BIOMARKAPD/ABSI and τP-181 /Aβ42 ratio classify 40% of "probable CBD" patients as AD. A consensus on the interpretation criteria of CSF AD biomarkers is pivotal. Current CBD diagnostic criteria misclassify many AD patients as having "probable CBD".